Advanced treatments like CAR-T cell therapy and bone marrow transplants are significantly improving outcomes for lymphoma patients, experts highlight...
Vous n'êtes pas connecté
Imugene's stock has surged this morning, on promising Phase 1b results for its azer-cel allogeneic CAR T-cell therapy. ...
Advanced treatments like CAR-T cell therapy and bone marrow transplants are significantly improving outcomes for lymphoma patients, experts highlight...
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
An experimental mRNA cancer vaccine shows promising results in a Phase 1 trial, potentially offering new hope for advanced-stage cancer patients.
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
Highlights: Secondary Primary Malignancy rates did not significantly differ among various CAR T-cell therapies or c
Highlights: Secondary Primary Malignancy rates did not significantly differ among various CAR T-cell therapies or c
Learn why the FDA has mandated boxed warnings for CAR T-cell therapies, highlighting the risks of secondary malignancies.
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...